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l 
UPPER-ABDOMINAL EXENTERATION IN TRANSPLANTATION FOR EXTENSIVE MALIGNANCIES OF THE 
UPPER ABDOMEN-AN UPDATE l 
Upper-abdominal exenteration (resection of the liver, pan-
creas, spleen, stomach, duodenum, and usually part of the 
colon) has been proposed for treatment of otherwise unresect-
able tumors (1). Replacement of the removed organs was orig-
inally with a liver homograft in continuity with the donor 
pancreas and a segment of duodenum. With a simplified version 
of this operation, only the liver is replaced, accepting the 
penalty of diabetes mellitus (2). The longest survivor following 
upper-abdominal exenteration now is approaching 2 years. We 
report here a follow-up on all 37 patients treated with these 
procedures through the end of 1989. 
IThis work was supported by research grants from the Veterans 
Administration and Project Grant No. DK 29961 from the National 
Institutes of Health, Bethesda, MD. 
The actuarial survival at 1 year for the group is slightly better 
than 50% and is not significantly different with the two pro-
cedures (Fig. 1). Twenty-two of the 37 survivors have no 
evidence of recurrent tumor after 5-21 months. Six of the 
deaths were caused by technical complications. Four of these 
complications were after the more-complex cluster replace-
ments and were derivative from the pancreas (pancreatitis and 
pancreatic abscess: 2 cases; and pancreatitis and rupture of 
arterial pseudoaneurysm: 2 cases). Technical deaths with the 
liver replacement alone accounted for only 2 of the losses 
(postoperative bleeding: 1 case; and biliary leak: 1 case). 
Apart from technical problems, the principal factors influ-
encing survival were the type and extent of the primary tumor. 
Eight of the 11 patients operating on for neuroendocrine tumors 
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FIGURE 1. Survival of cluster Tx recipients, Pittsburgh, PA. 
o 
o 
, .. ,., .. , .....•.. ,...... ,-~ 
.. 
N 
............... o---------------------G 
• Positive Nodes n=4 
_? __ ~~C~~!y!D_~~_Dt~_DlD:D;l 
no 
C+l----------Dla~l----------P~K----------~K----------Ino 
Time After Transplant (days) 
FIGURE 2. Survival of HCC cluster Tx recipients, Pittsburgh, PA. 
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FIGURE 3. Survival of cholangio CA Tx recipients, Pittsburgh, PA. 
or sarcomas are alive, after a mean follow-up of 12.5 months 
(follow-up ranging from 4.5 to 21 months); none of the 8 
survivors have evidence of recurrence. Patients with the more 
common hepatocellular carcinomas (Fig. 2) and cholangiocar-
cinomas (Fig. 3) have fared less well, particularly if the lymph 
nodes were positive in the surgical specimen. Of 4 patients with 
hepatocellular carcinomas and positive lymph nodes, only one 
is currently alive and thought to be tumor free, approaching 1 
year postoperative. The exceptional patient had hepatocellular 
carcinoma of the fibrolamellar variety that is known to carry a 
better prognosis. Nine patients with cholangiocarcinoma had 
positive lymph nodes; 3 are still alive and without evidence of 
recurrence after 11 (2 cases) and 9 months. 
As previously emphasized (1), these patients suffer signifi-
cant nutritional consequences as a result of the surgery. The 
patients approach a point of emaciation at about 3 months 
after successful surgery and then maintain a body weight usu-
ally 30% lower than preoperatively. Interestingly, their level of 
activity has not been commensurately reduced. Their energy 
level has been sufficient to support full-time employment for 
most of the survivors. 
Current efforts are directed toward identifying the groups of 
patients who can benefit from the exenteration procedure, 
determining whether or not adjuvant chemotherapy or irradia-
tion is beneficial, and ascertaining means of improving the 
quality of life postoperatively. 
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